19 June 2013
Keywords: amgen, romiplostim, meets, phase, iii, endpoints, itp
Article | 17 December 2007
US biotechnology giant Amgen says that data from a trial of its developmental drug romiplostim indicate that it increased and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 December 2007
10 December 2007
18 June 2013
© 2013 thepharmaletter.com